ATE285794T1 - Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien - Google Patents
Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologienInfo
- Publication number
- ATE285794T1 ATE285794T1 AT01928654T AT01928654T ATE285794T1 AT E285794 T1 ATE285794 T1 AT E285794T1 AT 01928654 T AT01928654 T AT 01928654T AT 01928654 T AT01928654 T AT 01928654T AT E285794 T1 ATE285794 T1 AT E285794T1
- Authority
- AT
- Austria
- Prior art keywords
- agonists
- joint
- treatment
- bone pathologies
- retinoid antagonists
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
- 102000027483 retinoid hormone receptors Human genes 0.000 abstract 2
- 108091008679 retinoid hormone receptors Proteins 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000008468 bone growth Effects 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/552,823 US20030114482A1 (en) | 1999-12-15 | 2000-04-20 | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| PCT/US2001/012742 WO2001080894A2 (en) | 2000-04-20 | 2001-04-19 | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE285794T1 true ATE285794T1 (de) | 2005-01-15 |
Family
ID=24206947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01928654T ATE285794T1 (de) | 2000-04-20 | 2001-04-19 | Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030114482A1 (enExample) |
| EP (1) | EP1274456B1 (enExample) |
| JP (1) | JP2003531180A (enExample) |
| AT (1) | ATE285794T1 (enExample) |
| AU (3) | AU2001255488B2 (enExample) |
| CA (1) | CA2407021A1 (enExample) |
| DE (1) | DE60108094T2 (enExample) |
| HK (1) | HK1053053B (enExample) |
| WO (1) | WO2001080894A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1701934B1 (en) * | 2003-12-26 | 2009-02-25 | Allergan, Inc. | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY |
| JP2007070281A (ja) * | 2005-09-06 | 2007-03-22 | Matsumoto Shika Univ | レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤 |
| US8680153B2 (en) * | 2005-12-13 | 2014-03-25 | The Royal Institution For The Advancement Of Learning/Mcgill University | Method for correcting a lipid imbalance in a subject |
| US20090209601A1 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteoarthritis |
| CN111773213B (zh) | 2010-09-01 | 2023-02-24 | 托马斯杰弗逊大学 | 用于肌肉修复和再生的组合物和方法 |
| US20140094512A1 (en) * | 2012-10-02 | 2014-04-03 | Nikolas Gunkel | Method of modulating the degree of adipose tissue deposited intramuscularly |
| WO2014073209A1 (ja) | 2012-11-08 | 2014-05-15 | 国立大学法人山口大学 | 角結膜障害の治療剤 |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| US10702502B2 (en) | 2013-05-22 | 2020-07-07 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
| ES2963348T3 (es) | 2016-06-08 | 2024-03-26 | Clementia Pharmaceuticals Inc | Métodos para tratar la osificación heterotópica |
| JP7018957B2 (ja) | 2016-11-16 | 2022-02-14 | クレメンティア ファーマシューティカルズ インコーポレイテッド | 多発性骨軟骨腫（ｍｏ）を処置するための方法 |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
| US5977125A (en) * | 1994-10-31 | 1999-11-02 | Eisai Co., Ltd. | Mono-or polyenic carboxylic acid derivatives |
| US5514825A (en) * | 1994-12-29 | 1996-05-07 | Allergan, Inc. | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
| US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
| DE19501032A1 (de) * | 1995-01-14 | 1996-07-18 | Max Delbrueck Centrum | Mittel zur Behandlung von rheumatischen Erkrankungen |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| KR100485642B1 (ko) * | 1996-03-18 | 2005-09-30 | 에자이 가부시키가이샤 | 축합고리함유카르복실산유도체 |
| US5808124A (en) * | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| US5773594A (en) * | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| US5763635A (en) * | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
| US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
| US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
| US5760276A (en) * | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
| US5962707A (en) * | 1998-08-18 | 1999-10-05 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D3 compounds with calcemic activity |
| CA2254429A1 (en) * | 1998-11-19 | 2000-05-19 | Tully Michael Underhill | Compositions for promoting chondrogenesis |
| DE19910246A1 (de) * | 1999-03-08 | 2000-09-28 | Bayer Ag | Trennfreundliche Polyurethan-Formschaum-Systeme |
| CA2402413A1 (en) * | 2000-03-14 | 2001-09-20 | The University Of Western Ontario | Compositions and methods for affecting osteogenesis |
-
2000
- 2000-04-20 US US09/552,823 patent/US20030114482A1/en not_active Abandoned
-
2001
- 2001-04-19 HK HK03105084.3A patent/HK1053053B/en not_active IP Right Cessation
- 2001-04-19 AU AU2001255488A patent/AU2001255488B2/en not_active Ceased
- 2001-04-19 AU AU5548801A patent/AU5548801A/xx active Pending
- 2001-04-19 DE DE60108094T patent/DE60108094T2/de not_active Expired - Fee Related
- 2001-04-19 EP EP01928654A patent/EP1274456B1/en not_active Expired - Lifetime
- 2001-04-19 WO PCT/US2001/012742 patent/WO2001080894A2/en not_active Ceased
- 2001-04-19 AT AT01928654T patent/ATE285794T1/de not_active IP Right Cessation
- 2001-04-19 CA CA002407021A patent/CA2407021A1/en not_active Abandoned
- 2001-04-19 JP JP2001577990A patent/JP2003531180A/ja active Pending
-
2006
- 2006-10-27 AU AU2006233216A patent/AU2006233216A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60108094T2 (de) | 2005-12-15 |
| WO2001080894A3 (en) | 2002-07-25 |
| AU5548801A (en) | 2001-11-07 |
| HK1053053A1 (en) | 2003-10-10 |
| HK1053053B (en) | 2005-06-10 |
| JP2003531180A (ja) | 2003-10-21 |
| EP1274456B1 (en) | 2004-12-29 |
| AU2001255488B2 (en) | 2006-07-27 |
| US20030114482A1 (en) | 2003-06-19 |
| WO2001080894A2 (en) | 2001-11-01 |
| DE60108094D1 (de) | 2005-02-03 |
| EP1274456A2 (en) | 2003-01-15 |
| CA2407021A1 (en) | 2001-11-01 |
| AU2006233216A1 (en) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001043732A3 (en) | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies | |
| EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
| DE60108094D1 (de) | Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien | |
| DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| DE60120372D1 (de) | Verwendung von insulin zur behandlung von knorpelkrankheiten | |
| DE60220887D1 (de) | Agonisten von beta-adrenorezeptoren | |
| EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
| DE60225556D1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
| CY1111912T1 (el) | Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων | |
| BRPI0417376A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| DK1315506T3 (da) | Phospholipidderivater af valproinsyre og blandinger deraf | |
| ATE338036T1 (de) | Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| DE60042446D1 (de) | Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen | |
| DE69917317D1 (de) | Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DE60312684D1 (de) | Plazenta-wachstumsfaktor als target für die behandlung von osteoporose | |
| DE602004024871D1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
| ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |